Synapse - Stephen Nimer

Results (24)

Risk-adapted melphalan with stem cell transplant (SCT) and adjuvant dexamethasone (dex) +/- thalidomide (thal) achieves low treatment related mortality and high hematologic response rates

Book Section

Cohen, A. D.; Zhou, P.; Reich, L.; Hassoun, H.; Teruya-Feldstein, J.; Filippa, D. A.; Clark, B.; Stubblefield, M.; Fleisher, M.; Nimer, S. D.; more...
In Skinner, M.; Berk, J. L.; Connors, L. H.; Seldin, D. C. (Eds.) XIth International Symposium on Amyloidosis (2008)

Fulltext@MSK | Save

CD32B expression reflects phenotypic and functional heterogeneity in multiple myeloma (MM)

Meeting Abstract

Zhou, P.; Boruchov, A. M.; Hoffman, J. E.; Mo, Q. X.; Olshen, A.; Glasner, E.; Bonvini, E.; Koenig, S.; Drieghe, E.; Fleisher, M.; more...
Blood (2008)

Fulltext@MSK | Save

Depletion of L3MBTL1, a PcG gene deleted in patients with 20q-associated with hematologic malignancies, accelerates erythroid differentiation of hematopoietic progenitor cells

Meeting Abstract

Perna, F.; Gurvich, N.; Hoya-Arias, R.; Voza, F.; Jankovic, V.; Kalakonda, N.; Nimer, S. D.
Blood (2008)

Fulltext@MSK | Save

Normalization of FDG-PET pre-ASCT with additional non-cross resistant chemotherapy improves EFS in patients with relapsed and primary refractory Hodgkin lymphoma - Memorial Sloan Kettering protocol 04-047

Meeting Abstract

Moskowitz, C. H.; Nimer, S. D.; Zelenetz, A. D.; Hamlin, P. A.; Horwitz, S. M.; Noy, A.; Portlock, C. S.; Straus, D. J.; Gerecitano, J.; Kewalramani, T.; more...
Blood (2008)

Fulltext@MSK | Save

Pre-transplant evaluation with both CT and PET following second-line therapy is essential for predicting outcome in patients with transplant-eligible relapsed and primary refractory Hodgkin lymphoma

Meeting Abstract

Moskowitz, A. J.; Nimer, S. D.; Zelenetz, A. D.; Kewalramani, T.; Vanak, J. M.; Maragulia, J. C.; Yahalom, J.; Moskowitz, C.
Blood (2008)

Fulltext@MSK | Save

Sequential administration of bortezomib, liposomal doxorubicin and dexamethasone (BDD) followed by thalidomide and dexamethasone (TD) results in rapid control of untreated high-risk multiple myeloma (MM) and improves depth of response

Meeting Abstract

Landau, H.; Hassoun, H.; Cohen, A.; Hoover, E.; Kewalramani, T.; Boruchov, A.; Klimek, V.; Reich, L.; Riedel, E.; Pandit-Taskar, N.; more...
Blood (2008)

Fulltext@MSK | Save

Previously unknown interactions between AML1 and MLL provide epigenetic regulation of gene expression in normal hematopoiesis and in leukemia

Meeting Abstract

Huang, G.; Elf, S.; Yan, X. M.; Wang, L.; Liu, Y.; Sashida, G.; Gural, A.; Menendez, S.; Lee, J.; Yang, Y. Y.; more...
Blood (2008)

Fulltext@MSK | Save

Early adjuvant treatment after risk-adapted autologous stem cell transplant for systemic light-chain amyloidosis: Increased hospitalizations and impaired immune recovery but improved responses and overall survival

Meeting Abstract

Hoffman, J. E.; Hassoun, H.; Landau, H.; Hoover, E.; Cohen, A.; Nimer, S.; Comenzo, R.
Blood (2008)

Fulltext@MSK | Save

CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy